Quality-adjusted life years in cancer: Pros, cons, and alternatives

European Journal of Cancer Care

Volumn 22, Issue 1, 2013, Pages 12-19

  Woodward, R M ^a   Menzin, Joseph ^a   Neumann, P J ^b  

^a Boston Health Economics Inc   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

Cost effectiveness; Oncology; Policy; QALY; Value

Indexed keywords

ARTICLE; COST BENEFIT ANALYSIS; ECONOMICS; HUMAN; METHODOLOGY; NEOPLASM; OUTCOME ASSESSMENT; QUALITY ADJUSTED LIFE YEAR; RESOURCE ALLOCATION;

COST-BENEFIT ANALYSIS; HUMANS; NEOPLASMS; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY-ADJUSTED LIFE YEARS; RESOURCE ALLOCATION;

EID: 84871720678     PISSN: 09615423     EISSN: 13652354     Source Type: Journal    
DOI: 10.1111/ecc.12006     Document Type: Article

References (85)

1. 111th Congress (2009) Patient Protection and Affordable Care Act (accessed 18 March 2011).
2. Annemans L. (2010) How health economic evaluation is used in drug reimbursement decisions in Europe. Available at: http://id.novartis.com/download-eminarEN.shtml (accessed 18 March 2011).
3. Appleby J., Devlin N. & Parkin D. (2007) NICE's cost effectiveness threshold. BMJ (Clinical Research Ed.) 335, 358-359.
4. Bach P.B. (2009) Limits on Medicare's ability to control rising spending on cancer drugs. The New England Journal of Medicine 360, 626-633.
5. Baumann R., Putz C., Rohrig B., Hoffken K. & Wedding U. (2009) Health-related quality of life in elderly cancer patients, elderly non-cancer patients and an elderly general population. European Journal of Cancer Care 18, 457-465.
6. Benyamini Y., McClain C.S., Leventhal E.A. & Leventhal H. (2003) Living with the worry of cancer: health perceptions and behaviors of elderly people with self, vicarious, or no history of cancer. Psycho-Oncology 12, 161-172.
7. Brazier J.E., Dixon S. & Ratcliffe J. (2009) The role of patient preferences in cost-effectiveness analysis: a conflict of values? Pharmacoeconomics 27, 705-712.
8. Bridges J.F., Onukwugha E. & Mullins C.D. (2010) Healthcare rationing by proxy: cost-effectiveness analysis and the misuse of the $50000 threshold in the US. Pharmacoeconomics 28, 175-184.
9. van Busschbach J. (2009) How to weigh cost effectiveness in appraisal
10. Chernew M.E. & Fendrick A.M. (2009) Value Based Insurance Design: Restoring Health To The Health Care Cost Debate. Available at: http://www.soa.org/library/essays/health-essay-2009-chernew.pdf (accessed 28 February 2011).
11. Connock M., Burls A., Frew E., Fry-Smith A., Juarez-Garcia A., McCabe C., Wailoo A., Abrams K., Cooper N., Sutton A., O'Hagan A. & Moore D. (2006) The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review. Health Technology Assessment (Winchester, England) 10, iii-136.
12. Davidoff A.J., Tang M., Seal B. & Edelman M.J. (2010) Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. Journal of Clinical Oncology 28, 2191-2197.
13. Dobrez D., Cella D., Pickard A.S., Lai J.S. & Nickolov A. (2007) Estimation of patient preference-based utility weights from the functional assessment of cancer therapy - general. Value in Health 10, 266-272.
14. Dranitsaris G., Ortega A., Lubbe M.S. & Truter I. (2012) A pharmacoeconomic modeling approach to estimate a value-based price for new oncology drugs in Europe. Journal of Oncology Pharmacy Practice 18, 57-67.
15. Drummond M., Dubois D., Garattini L., Horisberger B., Jonsson B., Kristiansen I.S., Le P.C., Pinto C.G., Poulsen P.B., Rovira J., Rutten F., von der Schulenburg M.G. & Sintonen H. (1999) Current trends in the use of pharmacoeconomics and outcomes research in Europe. Value in Health 2, 323-332.
16. Economist Intelligence Unit Limited (2009) Breakaway: the global burden of cancer - challenges and opportunities. Available at: http://blog.livestrong.org/2010/08/19/global-cancer-congress/ (accessed 12 May 2011).
17. Essink-Bot M.L., Korfage I.J. & De Koning H.J. (2003) Including the quality-of-life effects in the evaluation of prostate cancer screening: expert opinions revisited? BJU International 92 (Suppl. 2), 101-105.
18. Faden R.R., Chalkidou K., Appleby J., Waters H.R. & Leider J.P. (2009) Expensive cancer drugs: a comparison between the United States and the United Kingdom. The Milbank Quarterly 87, 789-819.
19. Festoy H., Sveen K., Yu L.M., Gjonnes L. & Gregersen T. (2008) Pharmaceutical Pricing and Reimbursement Information (accessed 18 March 2011).
20. Gafni A. (1997) Alternatives to the QALY measure for economic evaluations. Supportive Care in Cancer 5, 105-111.
21. Garau M., Shah K., Towse A., Wang Q., Drummond M. & Mason A. (2010) Report for the Pharmaceutical Oncology Initiative Group: assessment and appraisal of oncology medicines: does NICE's approach include all relevant elements? What can be learnt from international HTA experiences?
22. Gold M.R., Stevenson D. & Fryback D.G. (2002) HALYS and QALYS and DALYS, Oh My: similarities and differences in summary measures of population Health. Annual Review of Public Health 23, 115-134.
23. Gold M.R., Sofaer S. & Siegelberg T. (2007) Medicare and cost-effectiveness analysis: time to ask the taxpayers. Health Affairs (Project Hope) 26, 1399-1406.
24. Greenberg D., Earle C., Fang C.H., Eldar-Lissai A. & Neumann P.J. (2010) When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology. Journal of the National Cancer Institute 102, 82-88.
25. Gross C.P., Anderson G.F. & Powe N.R. (1999) The relation between funding by the National Institutes of Health and the burden of disease. The New England Journal of Medicine 340, 1881-1887.
26. Gupta D., Braun D.P. & Staren E.D. (2012) Association between changes in quality of life scores and survival in non-small cell lung cancer patients. European Journal of Cancer Care 21, 614-622.
27. Hammitt J.K. & Liu J.T. (2004) Risk in perspective: is there a 'cancer premium'? Harvard Center for Risk Analysis, 12, Issue 2.
28. Hardy D., Cormier J.N., Xing Y., Liu C.C., Xia R. & Du X.L. (2010) Chemotherapy-associated toxicity in a large cohort of elderly patients with non-small cell lung cancer. Journal of Thoracic Oncology 5, 90-98.
29. Harris G. (2008) British Balance Benefit vs. Cost of Latest Drugs. Available at: http://www.nytimes.com/2008/12/03/health/03nice.html (accessed 12 May 2011).
30. Hughes B. (2007) Novel risk-sharing scheme puts the spotlight on biomarkers. Available at: http://www.nature.com/nrd/journal/v6/n12/full/nrd2478.html (accessed 16 May 2011).
31. Hunter C.A., Glasspool J., Cohen R. & Keskinaslan A. (2010) A Literature Review of Risk-sharing Agreements. Available at: http://www.kamcp.or.kr/journal/pdf/2010_journal_1.pdf
32. Institute for Quality and Efficiency in Health Care (IQWIG) (2009) General Methods for the Relation of Benefits to Costs. Available at: http://www.ispor.org/peguidelines/source/Germany_AssessmentoftheRelationofBenefitstoCosts_En.pdf (accessed 18 March 2011).
33. International Society for Pharmacoeconomics and Outcomes Research (2007a) ISPOR Global Health Care Systems Road Map: Canada - Reimbursement Process. Available at: http://www.ispor.org/htaroadmaps/canada.asp (accessed 18 March 2011).
34. International Society for Pharmacoeconomics and Outcomes Research (2007b) ISPOR Global Health Care Systems Road Map: The Netherlands - Pharmaceuticals. Available at: http://www.ispor.org/htaroadmaps/netherlands.asp (accessed 18 March 2011).
35. International Society for Pharmacoeconomics and Outcomes Research (2009a) ISPOR Global Health Care Systems Road Map: Denmark - Pharmaceuticals. Available at: http://www.ispor.org/htaroadmaps/denmark.asp (accessed 18 March 2011).
36. International Society for Pharmacoeconomics and Outcomes Research (2009b) ISPOR Global Health Care Systems Road Map: Germany - Pharmaceuticals. Available at: http://www.ispor.org/htaroadmaps/germany.asp (accessed 18 March 2011).
37. International Society for Pharmacoeconomics and Outcomes Research (2009c) ISPOR Global Health Care Systems Road Map: Ireland - Pharmaceuticals. Available at: http://www.ispor.org/htaroadmaps/ireland.asp (accessed 18 March 2011).
38. International Society for Pharmacoeconomics and Outcomes Research (2009d) ISPOR Global Health Care Systems Road Map: Sweden - Pharmaceuticals. Available at: http://www.ispor.org/htaroadmaps/sweden.asp (accessed 18 March 2011).
39. Joerger M., Matter-Walstra K., Fruh M., Kuhnel U., Szucs T., Pestalozzi B. & Schwenkglenks M. (2010) Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis. Annals of Oncology 22, 567-574.
40. Kahneman D. & Thaler R. (2006) Anomalies: utility maximization and experienced utility. The Journal of Economic Perspectives 20, 221-234.
41. Kaplan R.M., Feeny D. & Revicki D.A. (1993) Methods for assessing relative importance in preference based outcome measures. Quality of Life Research 2, 467-475.
42. Kornblith A.B., Lan L., Archer L., Partridge A., Kimmick G., Hudis C., Winer E., Casey R., Bennett S., Cohen H.J. & Muss H.B. (2011) Quality of life of older patients with early-stage breast cancer receiving adjuvant chemotherapy: a companion study to cancer and leukemia group B 49907. Journal of Clinical Oncology 29, 1022-1028.
43. Kozminski M.A., Neumann P.J., Nadler E.S., Jankovic A. & Ubel P.A. (2011) How long and how well: oncologists' attitudes toward the relative value of life-prolonging vs. quality of life-enhancing treatments. Medical Decision Making 31, 380-385.
44. Lang K., Sussman M., Friedman M., Su J., Kan H.J., Mauro D., Tafesse E. & Menzin J. (2009) Incidence and costs of treatment-related complications among patients with advanced squamous cell carcinoma of the head and neck. Archives of Otolaryngology - Head and Neck Surgery 135, 582-588.
45. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., de Oliveira A.C., Santoro A., Raoul J.L., Forner A., Schwartz M., Porta C., Zeuzem S., Bolondi L., Greten T.F., Galle P.R., Seitz J.F., Borbath I., Haussinger D., Giannaris T., Shan M., Moscovici M., Voliotis D. & Bruix J. (2008) Sorafenib in advanced hepatocellular carcinoma. The New England Journal of Medicine 359, 378-390.
46. McGregor M. & Caro J.J. (2006) QALYS: are they helpful to decision makers? Pharmacoeconomics 24, 947-952.
47. McKenzie L. & van der Pol M. (2009) Mapping the EORTC QLQ C-30 onto the EQ-5D instrument: the potential to estimate QALYs without generic preference data. Value in Health 12, 167-171.
48. McNamee P. (2007) What difference does it make? The calculation of QALY gains from health profiles using patient and general population values. Health Policy (Amsterdam, Netherlands) 84, 321-331.
49. Meropol N.J., Schrag D., Smith T.J., Mulvey T.M., Langdon R.M., Jr, Blum D., Ubel P.A. & Schnipper L.E. (2009) American Society of Clinical Oncology guidance statement: the cost of cancer care. Journal of Clinical Oncology 27, 3868-3874.
50. Milne D.J., Mulder L.L., Beelen H.C., Schofield P., Kempen G.I. & Aranda S. (2006) Patients' self-report and family caregivers' perception of quality of life in patients with advanced cancer: how do they compare? European Journal of Cancer Care 15, 125-132.
51. Nadler E., Eckert B. & Neumann P.J. (2006) Do oncologists believe new cancer drugs offer good value? The Oncologist 11, 90-95.
52. National Institutes of Health (2010) Estimates of funding for various research, condition, and disease categories (RCDC). Available at: http://report.nih.gov/rcdc/categories/ (accessed 30 September 2010).
53. Neumann P.J. (2011) What next for QALYs? JAMA 305, 1806-1807.
54. Neumann P.J. & Greenberg D. (2009) Is the United States ready for QALYs? Health Affairs (Project Hope) 28, 1366-1371.
55. Neumann P.J. & Weinstein M.C. (2010) Legislating against use of cost-effectiveness information. The New England Journal of Medicine 363, 1495-1497.
56. Neumann P.J., Kamae M.S. & Palmer J.A. (2008) Medicare's national coverage decisions for technologies, 1999-2007. Health Affairs (Project Hope) 27, 1620-1631.
57. Neumann P.J., Auerbach H.R., Cohen J.T. & Greenberg D. (2010) Low-value services in value-based insurance design. The American Journal of Managed Care 16, 280-286.
58. Neumann P.J., Bliss S.K. & Chambers J.D. (2012) Therapies for advanced cancerspose a special challenge for health technology assessment organizations in many countries. Health Affairs (Project Hope) 31, 700-708.
59. Nierengarten M.B. (2010) Global cost-sharing programs for pricey drugs fall short. Available at: http://www.cancernetwork.com/news/display/article/10165/1568518 (accessed 20 May 2010).
60. Olin G.L. & Rhoades J.A. (2005) The five most costly medical conditions, 1997 and 2002: estimated for the U.S. Civilian Noninstitutionalized Population (Statistical Brieg #80). Available at: http://meps.ahrq.gov/mepsweb/data_files/publications/st80/stat80.pdf (accessed 30 September 2010).
61. Österreichisches Bundesinstitut für Gesundheitswese (2006) Surveying, Assessing and Analysing the Pharmaceutical Sector in the 25 EU Member States. Available at: http://ec.europa.eu/competition/mergers/studies_reports/oebig.pdf (accessed 16 May 2011).
62. Paul B., Trovato J.A. & Thompson J. (2008) Lapatinib: a dual tyrosine kinase inhibitor for metastatic breast cancer. American Journal of Health-System Pharmacy 65, 1703-1710.
63. Perrone M. (2010) Medicare panel backs costly cancer drug Provenge. Available at: http://www.fox19.com/story/13521232/medicare-panel-voices-confidence-in-cancer-drug?clienttype=printable&redirected=true (accessed 12 May 2011).
64. Pollack A. (2011) A Panel Decides Washington State's Health Care Costs. Available at: http://www.nytimes.com/2011/03/22/business/22care.html?_r=2 (accessed 23 March 2011).
65. Raftery J. (2009) NICE and the challenge of cancer drugs. BMJ (Clinical Research Ed.) 338, b67.
66. Ratcliffe J., Brazier J., Palfreyman S. & Michaels J. (2007) A comparison of patient and population values for health states in varicose veins patients. Health Economics 16, 395-405.
67. Rezo A., Dahlstrom J., Shadbolt B., Rodins K., Zhang Y. & Davis A.J. (2011) Tumor size and survival in multicentric and multifocal breast cancer. Breast (Edinburgh, Scotland) 20, 259-263.
68. Schickedanz A. (2009) Assessing and Improving Value in Cancer Care: Workshop Summary. Available at: http://www.nap.edu/catalog/12644.html (accessed 12 May 2011).
69. Schickedanz A. (2010) Of value: a discussion of cost, communication, and evidence to improve cancer care. The Oncologist 15 (Suppl. 1), 73-79.
70. Schoen C. & Osborn R. (2010) The Commonwealth Fund 2010 International Health Policy Survey in Eleven Countries. Available at: http://www.commonwealthfund.org/~/media/Files/Publications/In%20the%20Literature/2010/Nov/Int%20Survey/PDF_2010_IHP_Survey_Chartpack_11182010_FINAL_white_bkgd.pdf (accessed 4 May 2011).
71. Sommers B.D., Beard C.J., D'Amico A.V., Kaplan I., Richie J.P. & Zeckhauser R.J. (2008) Predictors of patient preferences and treatment choices for localized prostate cancer. Cancer 113, 2058-2067.
72. Stiggelbout A.M. & de Haes J.C. (2001) Patient preference for cancer therapy: an overview of measurement approaches. Journal of Clinical Oncology 19, 220-230.
73. Tangka F.K., Trogdon J.G., Richardson L.C., Howard D., Sabatino S.A. & Finkelstein E.A. (2010) Cancer treatment cost in the United States: has the burden shifted over time? Cancer 116, 3477-3484.
74. Thome B. & Hallberg I.R. (2004) Quality of life in older people with cancer - a gender perspective. European Journal of Cancer Care 13, 454-463.
75. Torrance G.W. (1986) Measurement of health state utilities for economic appraisal. Journal of Health Economics 5, 1-30.
76. Towse A. (2010) Value based pricing, research and development, and patient access schemes. Will the United Kingdom get it right or wrong? British Journal of Clinical Pharmacology 70, 360-366.
77. Ubel P.A. (2010) Beyond costs and benefits: understanding how patients make health care decisions. The Oncologist 15 (Suppl. 1), 5-10.
78. Ubel P.A., Nord E., Gold M., Menzel P., Prades J.L. & Richardson J. (2000) Improving value measurement in cost-effectiveness analysis. Medical Care 38, 892-901.
79. United Kingdom Department of Health (2010) Equity and Excellence: Liberating the NHS. Available at: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_117353 (accessed 28 February 2011).
80. United Kingdom Department of Health (2011) A new value-based approach to the pricing of branded medicines. Available at: http://www.dh.gov.uk/en/Consultations/Liveconsultations/DH_122760 (accessed 28 February 2011).
81. Vemer P. & Rutten-van Molken M.P. (2011) Largely ignored: the impact of the threshold value for a QALY on the importance of a transferability factor. The European Journal of Health Economics 12, 397-404.
82. Williamson S. (2010) Patient access schemes for high-cost cancer medicines: good in theory, difficult in practice. Available at: http://www.physorg.com/news184169787.html (accessed 29 March 2011).
83. Wonder M. & De Abreu Lourenco R. (2003) Factors considered in pharmaceutical reimbursement in Australia: a role for the rule of rescue? Available at: http://www.ispor.org/research_pdfs/2/pdffiles/PHP8.pdf
84. Zhou X., Cella D., Cameron D., Amonkar M.M., Segreti A., Stein S., Walker M. & Geyer C.E. (2009) Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment. Breast Cancer Research and Treatment 117, 577-589.
85. Zikmund-Fisher B.J., Fagerlin A. & Ubel P.A. (2010) Risky feelings: why a 6% risk of cancer does not always feel like 6%. Patient Education and Counseling 81 (Suppl.), S87-93.